UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 65

Sortiert nach

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

The New England journal of medicine, 2019-07, Vol.381 (4), p.317-327

2019

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Journal of clinical oncology, 2022-12, Vol.40 (34), p.3929-3939

2022

Link zum Volltext

Verfügbarkeit prüfen

Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply

The New England journal of medicine, 2019-10, Vol.381 (15), p.1492-1493

2019

Link zum Volltext

Verfügbarkeit prüfen

ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer

Journal of clinical oncology, 2006-11, Vol.24 (33), p.5313-5327

2006

Link zum Volltext

Verfügbarkeit prüfen

Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial

Journal of clinical oncology, 2020-05, Vol.38 (13), p.1442-1454

2020

Link zum Volltext

Verfügbarkeit prüfen

Patient‐centered outcomes in the POLO study of active maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer

Cancer, 2023-05, Vol.129 (9), p.1411-1418

2023

Link zum Volltext

Verfügbarkeit prüfen

Quality of Life of Postmenopausal Women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial

Journal of clinical oncology, 2004-11, Vol.22 (21), p.4261-4271

2004

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

Journal of clinical oncology, 2005-11, Vol.23 (31), p.8033-8040

2005

Link zum Volltext

Verfügbarkeit prüfen

Quality of life of postmenopausal women in the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer

Breast cancer research and treatment, 2006-12, Vol.100 (3), p.273-284

2006

Link zum Volltext

Verfügbarkeit prüfen

2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology

Journal of clinical oncology, 2001-03, Vol.19 (6), p.1865-1878

2001

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer : A us healthcare system perspective. the 5-year completed treatment analysis of the ATAC ('arimidex', tamoxifen alone or in combination) trial

Breast cancer research and treatment, 2007-12, Vol.106 (2), p.229-238

2007

Link zum Volltext

Verfügbarkeit prüfen

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

The lancet oncology, 2017-12, Vol.18 (12), p.1637-1651

2017

Link zum Volltext

Verfügbarkeit prüfen

Oxaliplatin‐Related Acute Myelogenous Leukemia

The oncologist (Dayton, Ohio), 2006-03, Vol.11 (3), p.261-262

2006

Link zum Volltext

Verfügbarkeit prüfen

Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy

Cancer, 2004-08, Vol.101 (4), p.735-740

2004

Link zum Volltext

Verfügbarkeit prüfen

Defining the Roles of Aromatase Inhibitors in the Adjuvant Treatment of Early-Stage Breast Cancer

Clinical breast cancer, 2005-10, Vol.6 (4), p.302-309

2005

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT217: POLO: Homologous recombination repair gene mutations (HRRm) in metastatic pancreatic cancer (mPaC) tumors

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT217-CT217

2020

Link zum Volltext

Verfügbarkeit prüfen

Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.420-420

2021

Link zum Volltext

Verfügbarkeit prüfen

The spectrum of vascular lesions in the mammary skin, including angiosarcoma, after breast conservation treatment for breast cancer

Journal of the American College of Surgeons, 2001-07, Vol.193 (1), p.22

2001

Link zum Volltext

Verfügbarkeit prüfen

Genetic factors and colorectal cancer in Ashkenazi Jews

Familial cancer, 2004, Vol.3 (3-4), p.215-221

2004

Link zum Volltext

Verfügbarkeit prüfen

Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4621-4621

2020

Link zum Volltext

Verfügbarkeit prüfen

POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4626-4626

2020

Link zum Volltext

Verfügbarkeit prüfen

Maintenance Olaparib for Metastatic Pancreatic Cancer

The New England journal of medicine, 2019-10, Vol.381 (15), p.1491-1493

2019

Link zum Volltext

Verfügbarkeit prüfen

POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2 mutation (g BRCA m) who have not progressed following first-line chemotherapy

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS4149-TPS4149

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Olaparib (AZD‐2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer

The oncologist (Dayton, Ohio), 2016-02, Vol.21 (2), p.172-177

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial of Fixed Dose Rate Infusion Gemcitabine with Gefitinib in Patients with Pancreatic Carcinoma

Cancer investigation, 2007-01, Vol.25 (5), p.366-371

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 65

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(65)

Sprache

Englisch
(65)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Humans
(37)
Female
(31)
Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Oncology
(25)
Middle Aged
(22)
Adult
(17)
Aged
(17)
Male
(17)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Tumors
(11)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Adenocarcinoma - Drug Therapy
(6)
Breast Neoplasms - Drug Therapy
(6)
Cancer Research
(6)
Chemotherapy
(6)
Neoplasm Staging
(6)
Pancreatic Neoplasms - Drug Therapy
(6)
Pancreatic Neoplasms - Pathology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply

ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer

Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial

Patient‐centered outcomes in the POLO study of active maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer

Quality of Life of Postmenopausal Women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial

Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

Quality of life of postmenopausal women in the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer

2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer : A us healthcare system perspective. the 5-year completed treatment analysis of the ATAC ('arimidex', tamoxifen alone or in combination) trial

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

Oxaliplatin‐Related Acute Myelogenous Leukemia

Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy

Defining the Roles of Aromatase Inhibitors in the Adjuvant Treatment of Early-Stage Breast Cancer

Abstract CT217: POLO: Homologous recombination repair gene mutations (HRRm) in metastatic pancreatic cancer (mPaC) tumors

Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm)

The spectrum of vascular lesions in the mammary skin, including angiosarcoma, after breast conservation treatment for breast cancer

Genetic factors and colorectal cancer in Ashkenazi Jews

Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm)

POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC)

Maintenance Olaparib for Metastatic Pancreatic Cancer

POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2 mutation (g BRCA m) who have not progressed following first-line chemotherapy

Phase II Study of Olaparib (AZD‐2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer

Phase I Trial of Fixed Dose Rate Infusion Gemcitabine with Gefitinib in Patients with Pancreatic Carcinoma

Suchergebnisse filtern